rss
J Clin Pathol 2006;59:666-667
  • Correspondence

Therapeutic drug monitoring of vancomycin in patients receiving haemodialysis: time for a change

  1. F Fitzpatrick,
  2. T McGaley,
  3. L Rajan,
  4. R Crowley,
  5. M Turley,
  6. H Humphreys,
  7. E Smyth
  1. Department of Microbiology, Beaumont Hospital, Dublin, Republic of Ireland
  1. Correspondence to:
    F Fitzpatrik
    Department of Microbiology, Beaumont Hospital, Dublin, Republic of Ireland; fidelmafitz{at}eircom.net

    A polyclonal antibody-based fluorescence polarisation immunoassays (pFPIA) overestimates vancomycin levels in the serum of patients receiving haemodialysis.1 Prolonged exposure of vancomycin to body temperature in these patients allows vancomycin to break down into crystalline degradation products (CDP-1).2 Because of structural similarities between vancomycin and CDP-1, a pFPIA may falsely recognise and report CDP-1 as vancomycin. Despite this, most laboratories in the UK and in the Republic of Ireland, including ours, continue to use a pFPIA for therapeutic drug monitoring (TDM) of vancomycin.3 We wish to bring this issue to the attention of laboratories, as therapeutic decisions on the basis of levels that are falsely recognised as increased …

    Register for free content


    Free trial
    Individuals may register for a free 60 day online trial to all content.

    Free archive
    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they ar